TY - JOUR
T1 - From machine learning to deep learning
T2 - progress in machine intelligence for rational drug discovery
AU - Zhang, Lu
AU - Tan, Jianjun
AU - Han, Dan
AU - Zhu, Hao
N1 - Funding Information:
The authors thank the Chinese Natural Science Foundation Project (No. 21173014 ) for financial support.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/11
Y1 - 2017/11
N2 - Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence approaches have been applied to guide traditional experiments, which are expensive and time-consuming. Over the past several decades, machine-learning tools, such as quantitative structure–activity relationship (QSAR) modeling, were developed that can identify potential biological active molecules from millions of candidate compounds quickly and cheaply. However, when drug discovery moved into the era of ‘big’ data, machine learning approaches evolved into deep learning approaches, which are a more powerful and efficient way to deal with the massive amounts of data generated from modern drug discovery approaches. Here, we summarize the history of machine learning and provide insight into recently developed deep learning approaches and their applications in rational drug discovery. We suggest that this evolution of machine intelligence now provides a guide for early-stage drug design and discovery in the current big data era.
AB - Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence approaches have been applied to guide traditional experiments, which are expensive and time-consuming. Over the past several decades, machine-learning tools, such as quantitative structure–activity relationship (QSAR) modeling, were developed that can identify potential biological active molecules from millions of candidate compounds quickly and cheaply. However, when drug discovery moved into the era of ‘big’ data, machine learning approaches evolved into deep learning approaches, which are a more powerful and efficient way to deal with the massive amounts of data generated from modern drug discovery approaches. Here, we summarize the history of machine learning and provide insight into recently developed deep learning approaches and their applications in rational drug discovery. We suggest that this evolution of machine intelligence now provides a guide for early-stage drug design and discovery in the current big data era.
UR - http://www.scopus.com/inward/record.url?scp=85028803040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028803040&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2017.08.010
DO - 10.1016/j.drudis.2017.08.010
M3 - Review article
C2 - 28881183
AN - SCOPUS:85028803040
SN - 1359-6446
VL - 22
SP - 1680
EP - 1685
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 11
ER -